BGI Genomics Co

BGI Genomics Co Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of BGI Genomics Co (300676.SZ) as of Nov 3, 2026 is -57.91. In the previous year, Cash Conversion Cycle (CCC) was 74.60 — a change of -177.63% (lower).

Cash Conversion Cycle

-57.91

YoY

-177.63%

Last updated:

Cash Conversion Cycle (CCC) of BGI Genomics Co is 2025 -57.91 . Cash Conversion Cycle (CCC) of BGI Genomics Co was 2024 74.60 . It decreases by -177.63% lower compared to the previous year.

The BGI Genomics Co Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
213.03 CNY
Jan 1, 2019
220.68 CNY
Jan 1, 2020
82.55 CNY
Jan 1, 2021
74.82 CNY
Jan 1, 2022
82.75 CNY
Jan 1, 2023
77.67 CNY
Jan 1, 2024
74.60 CNY
Jan 1, 2025
-57.91 CNY
The BGI Genomics Co Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-57.91-177.63%
74.60-3.96%
77.67-6.14%
82.75+10.60%
74.82-9.36%
82.55-62.59%
220.68+3.59%
213.03+42.89%
149.09+7.43%
138.78-20.45%
174.47+33.12%
131.06—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BGI Genomics Co Stock analysis

What does BGI Genomics Co do? BGI Genomics Co., Ltd. generates revenue through its core services in genomics, including reproductive health basic research and clinical application services, basic science research services such as genome sequencing and bioinformatics analysis, complex disease research and clinical applications, and drug-related research services. The company primarily serves academic institutions, research institutes, independent laboratories, pharmaceutical companies, hospitals, and medical institutions both domestically and internationally. Its domestic market focus allows it to cater to a wide range of clients seeking advanced genomic solutions for research and healthcare applications. The firm's revenue streams are derived from providing specialized genomic services to institutions and companies involved in medical research and healthcare. By offering multithreaded solutions in genome sequencing and bioinformatics, BGI Genomics supports clients in advancing their scientific and clinical objectives. The company's domestic market operations enable it to maintain strong relationships with key stakeholders in China's healthcare and research sectors. BGI Genomics' service portfolio includes reproductive health, complex disease, and drug development research, all of which are critical areas for pharmaceutical and medical institutions. These services are tailored to meet the needs of academic and commercial clients, driving demand for its genomic analysis and research support. The company's focus on domestic operations ensures alignment with local healthcare and research priorities. BGI Genomics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BGI Genomics Co stock

Cash Conversion Cycle (CCC) of BGI Genomics Co is -57.91 in 2025.

Cash Conversion Cycle (CCC) of BGI Genomics Co changed from 74.60 to -57.91, representing a -177.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) BGI Genomics Co since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s BGI Genomics Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — BGI Genomics Co

All Key Metrics — BGI Genomics Co